(Q28343798)

2

0 references

P Shields

3

0 references

P Cane

4

0 references

D Ratcliffe

5

0 references

B Martin

6

0 references

S Buchan

7

0 references

L Boxall

8

0 references

K O'Donnell

9

0 references

J Shaw

10

0 references

S Hübscher

11

0 references

E Elias

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

12

0 references

language of work or name

English

0 references

publication date

January 2000

0 references

published in

Gut

0 references

volume

46

0 references

issue

1

0 references

page(s)

107-13

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727773

A preliminary trial of lamivudine for chronic hepatitis B infection

27 November 2018

1 reference

12 December 2020

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo

1 reference

12 December 2020

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

12 December 2020

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

12 December 2020